In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge Presented ByDr Thomas Yau, University of Hong Kong, China TrialPhase 3, CheckMate 459 ConferenceESMO 2019 TypePeer-reviewed article 26 November 2019 20:21